Patents Issued in July 6, 2017
  • Publication number: 20170189454
    Abstract: This disclosure provides, inter alia, systems and methods for storage and delivery of ammonia oxidizing bacteria, and preparations comprising ammonia oxidizing bacteria. The ammonia oxidizing bacteria may be provided in a container or a kit, with one or more other components that may enhance delivery. The systems and methods herein may be used, for instance, to treat diseases associated with low nitrite levels, skin diseases, and diseases caused by pathogenic bacteria.
    Type: Application
    Filed: May 21, 2015
    Publication date: July 6, 2017
    Inventors: James Heywood, Spiros Jamas, David R. Whitlock, Larry Weiss
  • Publication number: 20170189455
    Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.
    Type: Application
    Filed: December 20, 2016
    Publication date: July 6, 2017
    Inventors: Joseph A. Murray, Eric V. Marietta, Susan H. Barton, Veena Taneja, Ashutosh Mangalam
  • Publication number: 20170189456
    Abstract: The invention relates to a strain of Bacteroides uniformes with registration number CECT 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products. The invention further relates to the use of a strain of Bacteroides uniforms, preferably CECT 7771, or of the cellular constituents, metabolites and/or secreted molecules of said strain, or of a composition comprising same, for the prevention and/or treatment of alterations such as excess weight, obesity, adipocyte hypertrophy, hepatic steatosis or fatty liver, dyslipidemia, hyperglycemia, insulin resistance and diabetes, metabolic syndrome, hypertension, cardiovascular diseases, dysfunction of the immune system, reduced defences against infections, and imbalance in the composition of the intestinal microbiota.
    Type: Application
    Filed: March 14, 2017
    Publication date: July 6, 2017
    Inventors: Yolanda Sanz Herranz, Paola Gauffin Cano, Yolanda Arlette Santacruz, Angela Moya Perez, Moises Laparra Llopis
  • Publication number: 20170189457
    Abstract: The present application relates to nutritional compositions comprising lactic acid-producing bacteria.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 6, 2017
    Inventors: Sean Farmer, David Keller, Andrew R. Lefkowitz
  • Publication number: 20170189458
    Abstract: It is an object of the present invention to provide a lactic acid bacterial immunopotentiating activity-increasing composition that increases the immunopotentiating activity of lactic acid bacteria having immunopotentiating activity; and a method for increasing the immunopotentiating activity of lactic acid bacteria using the composition; and a composition comprising both of lactic acid bacteria having an immunopotentiating activity and a lactic acid bacterial immunopotentiating activity-increasing composition, wherein the immunopotentiating activity of the lactic acid bacteria is increased. The present invention relates to a composition comprising lactic acid bacteria having an immunopotentiating activity and a lactic acid bacterial immunopotentiating activity-increasing composition comprising an ester compound of a polyol and a saturated fatty acid as an active ingredient.
    Type: Application
    Filed: May 29, 2015
    Publication date: July 6, 2017
    Applicant: KIRIN COMPANY, LIMITED
    Inventors: Masaya KANAYAMA, Kyoko TAZUMI
  • Publication number: 20170189459
    Abstract: The present invention relates to a novel bacteriophage ?CJ24 (KCCM11462P) and a composition comprising the same as an active component. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic E. coli of birds by using the bacteriophage ?CJ24 (KCCM11462P) or the composition.
    Type: Application
    Filed: April 14, 2015
    Publication date: July 6, 2017
    Applicant: CJ CHEILJEDANG CORPORATION
    Inventors: Eun Mi SHIN, Gi Duk BAE, Jae Won KIM
  • Publication number: 20170189460
    Abstract: The present invention relates to a novel bacteriophage ?CJ26 (KCCM11464P) and a composition comprising the same as an active ingredient. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by Salmonella by using the bacteriophage ?CJ26 (KCCM11464P) or the composition.
    Type: Application
    Filed: April 14, 2015
    Publication date: July 6, 2017
    Applicant: CJ CHEILJEDANG CORPORATION
    Inventors: Eun Mi SHIN, Bo Kyung SON, Gi Duk BAE, Jae Won KIM
  • Publication number: 20170189461
    Abstract: This invention is related to a method of preparing a fermented crude extract having angiotensin converting enzyme inhibiting activity. The method comprises the following steps. A material is dried, milled, and then mixed with water in a weight ratio of 1:11 to form a mixture solution. 0.1 vol % ?-amylase is used to perform hydrolysis at 95° C. for 1 hour. 0.1 vol % glucoamylase is used to perform hydrolysis at 65° C. for 4 hours. A lactic acid bacterium is added in a culture medium containing the mixture solution to perform fermentation for 24 hours. The culture medium is centrifuged to take the supernatant thereof, and the supernatant is boiled for 20 minutes. The supernatant is filtered to obtain a fermented crude extract having angiotensin converting enzyme inhibiting activity.
    Type: Application
    Filed: December 31, 2015
    Publication date: July 6, 2017
    Inventors: SHU-CHEN WANG, PIN-DER DUH, SHIH-YING CHEN, CHEN-KAI CHANG, JUNG-TSAI CHEN, CHIH-KUANG CHIU
  • Publication number: 20170189462
    Abstract: A method for producing powderized cannabis oil, and the resulting powderized cannabis oil, in which concentrated cannabis oil is mixed with and absorbed by a modified starch powder, preferably maltodextrin, in a ratio of at least three grams of starch powder for every one-eighth of a gram of cannabis oil is disclosed. Further disclosed are beverages, baked goods and single-serve beverage brewing cartridges utilizing or incorporating the powderized cannabis oil to create human-consumable products that contain an emulsified, tasteless, and odorless dose of cannabis oil.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 6, 2017
    Applicant: ERS Holdings, LLC
    Inventors: Ross M. Franklin, Ed Rosenthal, Rachel M. Franklin
  • Publication number: 20170189463
    Abstract: A method for producing powderized cannabis oil, and the resulting powderized cannabis oil, in which concentrated cannabis oil is mixed with and absorbed by a modified starch powder, preferably maltodextrin, in a ratio of at least three grams of starch powder for every one-eighth of a gram of cannabis oil is disclosed. Further disclosed are beverages, baked goods and single-serve beverage brewing cartridges utilizing or incorporating the powderized cannabis oil to create human-consumable products that contain an emulsified, tasteless, and odorless dose of cannabis oil.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 6, 2017
    Applicant: ERS Holdings, LLC
    Inventors: Ross M. Franklin, Ed Rosenthal, Rachel M. Franklin
  • Publication number: 20170189464
    Abstract: Disclosed are a method for preparing a ginseng polysaccharide for immune stimulation and a ginseng polysaccharide for immune stimulation prepared from the preparation method, the method comprising the steps of (1) adding ingredients; (2) performing an extraction; (3) performing a first filtration and cooling; (4) performing a second filtration; (5) performing a first concentration; (6) adding a concentrate to a fermentation alcohol; (7) separating into a supernatant and a precipitate; (8) collecting the precipitate; (9) dissolving in water; (10) performing a second concentration; (11) cold ageing; (12) performing a third concentration; (13) sterilizing; and (14) packaging into a product of the ginseng polysaccharide for immune stimulation in the form of a concentrate.
    Type: Application
    Filed: April 27, 2015
    Publication date: July 6, 2017
    Applicant: HEALTH BIO MAD CO., LTD.
    Inventors: Seung Hui LEE, Gap Sun PARK, Geum Hui LEE
  • Publication number: 20170189465
    Abstract: With the object of providing a novel anti-hallucination agent capable of suppressing, treating or preventing a hallucinatory symptom, the anti-hallucination agent of the invention contains an Atractylodes-derived crude drug as an active ingredient or contains a compound represented by the following formula (Ia), a stereoisomer thereof or a salt thereof as an active ingredient: in the formula, the double lines consisting of a solid line and a broken line represent a single bond or a double bond; R1 represents a hydrogen atom or a hydroxyl group, with the proviso that R1 does not exist when the carbon atom to which R1 is attached is linked to one of the neighboring carbon atoms through a double bond; R2 represents a hydrogen atom or is combined with R3 to represent a cyclic group which may have a substituent; and R3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms which may have a substituent or is combined with R2 to represent a cyclic group which may have a substituent.
    Type: Application
    Filed: March 26, 2015
    Publication date: July 6, 2017
    Applicant: Kracie Pharma, Ltd.
    Inventors: Hisayoshi Norimoto, Chiaki Murayama, Seiwa Michihara
  • Publication number: 20170189466
    Abstract: The present invention relates to compositions comprising black cumin (Nigelia sativa seed) oil, olive oil, tea tree (Melaleuca alternifolia) oil, cocoa butter, vitamin A or a derivative thereof, and vitamin B12 or a derivative thereof. The compositions of the present invention can be advantageously used in the in the treatment of dermatological conditions, disorders or diseases, in particular inflammatory dermatological diseases such as psoriasis.
    Type: Application
    Filed: February 21, 2017
    Publication date: July 6, 2017
    Inventor: Thaher Kamal
  • Publication number: 20170189467
    Abstract: A composition for enhancement of ability to concentrate and method of improving ability to concentrate using alanylglutamine or a salt of alanylglutamine as an active ingredient.
    Type: Application
    Filed: May 22, 2015
    Publication date: July 6, 2017
    Inventors: Yukihiro Hishida, Takeshi Ikeda, Ryusuke Nakagiri, Ayako Kamimura
  • Publication number: 20170189468
    Abstract: The purpose of the present invention is to provide a novel tissue regeneration promoter and method for promoting tissue regeneration. The present invention pertains to: a composition for promoting tissue regeneration and/or promoting cell growth, the composition containing an RGD peptide; a method for promoting tissue regeneration and/or promoting cell growth using RGD peptide; and the like.
    Type: Application
    Filed: June 18, 2015
    Publication date: July 6, 2017
    Inventors: Yoshiro Niitsu, Akihiro Yoneda
  • Publication number: 20170189469
    Abstract: Medical devices comprising an anti-connexin agent suitable for introduction into a subject.
    Type: Application
    Filed: February 3, 2017
    Publication date: July 6, 2017
    Inventors: David BECKER, Colin GREEN, Bradford DUFT
  • Publication number: 20170189470
    Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.
    Type: Application
    Filed: March 15, 2017
    Publication date: July 6, 2017
    Inventors: Zhaolin Wang, Ping Ye, Alonso Ricardo, Kristopher Josephson, Paul Anderson, Michelle Denise Hoarty, Zhong Ma, Nathan Ezekiel Nims, Eberhard Schneider, Gregor Schurmann, Peter Wagner, Douglas A. Treco, Hong Zheng, Daniel Elbaum, Nicolas Cedric Boyer
  • Publication number: 20170189471
    Abstract: The invention provides methods for treating fibrosis and/or cancer in a subject in need thereof. The methods include providing a composition comprising an inhibitor of IL-4/IL-13 receptor function and administering an effective amount of the composition to the subject to treat fibrosis and/or cancer.
    Type: Application
    Filed: March 15, 2017
    Publication date: July 6, 2017
    Applicants: Cedars-Sinai Medical Center, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ramachandran Murali, Aida Habtezion, Stephen J. Pandol
  • Publication number: 20170189472
    Abstract: Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 <51> in preventing growth of specified bacteria and fungi.
    Type: Application
    Filed: March 21, 2017
    Publication date: July 6, 2017
    Inventor: Edward T. Maggio
  • Publication number: 20170189473
    Abstract: A composition containing wall teichoic acid-attached peptidoglycan (WTA-PGN) as an active ingredient, a method for preventing or treating Staphylococcus aureus infectious diseases using the composition, and a method for preparing a soluble WTA-PGN which can be used as an active ingredient in the composition are provided. The composition of the present invention can be effectively used for preventing or treating Staphylococcus aureus infectious diseases by opsonophagocytosis due to antigen-antibody reaction and neutrophil-mediated phagocytosis due to T cell activation at the early stage of infection.
    Type: Application
    Filed: May 29, 2015
    Publication date: July 6, 2017
    Applicants: GREEN CROSS CORPORATION, PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Bok Luel LEE, Min Ja LEE, Jong-Ho LEE, Min Young SEONG, Dong Ho AHN, Kazue TAKAHASHI, Kenji KUROKAWA
  • Publication number: 20170189474
    Abstract: The present invention provides for methods and systems for the treatment and diagnosis of Hirschsprung-associated enterocolitis. Treatment of Hirschsprung-associated enterocolitis can include providing and administering an antifungal agent or a combination of an antifungal agent and an antibiotic. Diagnosis of Hirschsprung-associated enterocolitis can include the detection of fungal species by way of qPCR.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 6, 2017
    Applicant: Cedars-Sinai Medical Center
    Inventor: Philip K. FRYKMAN
  • Publication number: 20170189475
    Abstract: The present invention relates to the treatment of patients with pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated.
    Type: Application
    Filed: August 4, 2014
    Publication date: July 6, 2017
    Inventors: Peter Wehling, Julio Reinecke
  • Publication number: 20170189476
    Abstract: The present invention relates to a fusion protein composed of the extracellular domain of PD-L1 and a modified immunoglobulin Fc region. The extracellular domain of PD-L1 and a fragment thereof have excellent immunomodulatory activity, and can be used as an immunomodulatory agent if a modified immunoglobulin Fc region is coupled thereto. Accordingly, the PD-L1 fusion protein according to the present invention demonstrated its excellent effect in disease models of inflammatory bowel disease, colitis, psoriasis, asthma and arthritis, and thus can be very effectively used for the treatment of such diseases.
    Type: Application
    Filed: May 26, 2015
    Publication date: July 6, 2017
    Applicants: GENEXINE, INC., POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Young Chul SUNG, Ji Yeung LEE, Mi-Young SONG, Hye Seong LIM, Byung Ha LEE
  • Publication number: 20170189477
    Abstract: In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof and agents that inhibit the expression of p27Kip1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof, which are useful for inducing the formation of cochlear hair cells; and methods of treating hearing impairments or disorders using the compositions. In one aspect, the invention relates to pharmaceutical compositions comprising ?-catenin; and agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: December 29, 2016
    Publication date: July 6, 2017
    Inventors: Jian Zuo, Taosheng Chen, Brandon Walters, Bryan Kuo, Bradley Walters
  • Publication number: 20170189478
    Abstract: The present invention relates to various polypeptides from fish hatching fluid, their encoding nucleic acid sequences, pharmaceutical compositions comprising said polypeptides and nucleic acid molecules and their use in various medical and cosmetic applications to the skin, particularly for moisturizing skin and/or for exfoliation of the horny layer of the skin for treating or preventing skin disorders or conditions in an animal.
    Type: Application
    Filed: March 6, 2017
    Publication date: July 6, 2017
    Applicant: AQUA BIO TECHNOLOGY ASA
    Inventors: Hans Kristian LEREN, Bernt Th. WALTHER
  • Publication number: 20170189479
    Abstract: Disclosed herein are compositions and articles for wound healing that contain proteovesicles, comprising a syndecan polypeptide embedded in a lipid vesicle, and a PDGF polypeptide. Also disclosed is the use of these compositions to enhance wound healing.
    Type: Application
    Filed: December 21, 2016
    Publication date: July 6, 2017
    Inventors: Aaron B. Baker, Subhamoy Das
  • Publication number: 20170189480
    Abstract: The invention provides a novel compounds derived from CD154, but without the intracellular domain. Notably, the invention provides TMZ-CD154 and a method to treat diseases in which the novel molecule TMZ-CD154 is used. In particular, TMZ-CD154 is used to modify the immune responses in patients with immune related diseases such as cancer and infectious disease. The invention also relates to a method to activate cells with the TMZ-CD154 in vitro either prior to using the activated cells for therapy or for diagnostic purposes.
    Type: Application
    Filed: April 7, 2015
    Publication date: July 6, 2017
    Applicant: LOKON PHARMA AB
    Inventor: Angelica Loskog
  • Publication number: 20170189481
    Abstract: The present disclosure related in general to methods of treating cancer by interfering with the interaction of metadherin with Staphylococcal nuclease domain-containing 1 (SND1) using peptides or other compounds that inhibit the binding of SND1 with metadherin and inhibit the activity of the MTDH-SND1 complex in tumor cells.
    Type: Application
    Filed: June 25, 2015
    Publication date: July 6, 2017
    Inventors: Yibin Kang, Yongna Xing, Liling Wan, Feng Guo
  • Publication number: 20170189482
    Abstract: In one aspect the present invention is directed to mutant Neutrophil Gelatinase Associated Lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.
    Type: Application
    Filed: December 12, 2016
    Publication date: July 6, 2017
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Jonathan BARASCH, Andong QIU
  • Publication number: 20170189483
    Abstract: The invention is directed, in part, to the use of gelsolin to diagnose, monitor, and treat subjects with renal failure (e.g., chronic renal failure subjects on dialysis).
    Type: Application
    Filed: January 17, 2017
    Publication date: July 6, 2017
    Inventors: RAVI THADHANI, THOMAS P. STOSSEL, PO-SHUN LEE, ANANTH KARUMANCHI
  • Publication number: 20170189484
    Abstract: The present invention relates to small peptides, derived from the N-terminal domain of CEACAM5 (carcinoembryonic antigen family member 5), with the ability to stimulate the suppressive activity of CD8+ T cells in Crohn's disease. Pharmaceutical formulations, methods to treat patients with Crohn's disease, and methods to identify candidate peptides for treatment of Crohn's disease patients, are also disclosed.
    Type: Application
    Filed: May 1, 2015
    Publication date: July 6, 2017
    Inventors: Giulia RODA, Lloyd MAYER
  • Publication number: 20170189485
    Abstract: This application provides methods of increasing vascularization, muscle performance, muscle rehabilitation, and/or mitochondrial activity in subjects in need thereof, by administering a therapeutically effective amount of one or more agents that increases ERR? activity to the subject. Such agents can include one or more ERR? agonists. In some examples the method does not require that the subject exercise, and as such, the subject may be sedentary (such as bedridden or in a wheelchair).
    Type: Application
    Filed: January 17, 2017
    Publication date: July 6, 2017
    Applicant: Salk Institute for Biological Studies
    Inventors: Vihang A. Narkar, Michael Downes, Ruth T. Yu, Ronald M. Evans
  • Publication number: 20170189486
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 6, 2017
    Inventors: Paul E. MORIN, Daniel COHEN, Ranjan MUKHERJEE, Timothy P. REILLY, Rose C. CHRISTIAN, Dasa LIPOVSEK, Ray CAMPHAUSEN, John KRUPINSKI
  • Publication number: 20170189487
    Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: April 24, 2015
    Publication date: July 6, 2017
    Inventors: Ryo Ohori, Kanta Horie
  • Publication number: 20170189488
    Abstract: Provided is a method for treating a peripheral nervous system damage or injury, or for regenerating peripheral nervous system tissue that involves administering to a subject in need thereof a vector that comprises polynucleotide sequences that encode vascular endothelia growth factor (VEGF) and fibroblast growth factor (FGF2) and further a polynucleotide that encodes resistance to kanamycin. A gene-therapeutic structure coding vascular endothelial growth factor (VEGF) and (FGF-2) is also provided. The gene-therapeutic structure can be administered directly to a damaged nerve and paraneural tissues both in intraoperative and post-operative period to stimulate peripheral nerve regeneration. The structure and method significantly advance existing methods for reconstructive treatment for damaged peripheral nerves.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 6, 2017
    Applicant: ''NEXTGEN'' COMPANY LIMITED
    Inventors: Artur Aleksandrovich ISAEV, Albert Anatolyevich Rizvanov, Ruslan Faridovich Masgutov, Aleksei Andreevich Bogov, IInur lldusovich Salafutdinov, Roman Vadimovich Deev, llya Yadigerovich Bozo, Igor Leonidovich Plaksa, Andrei Alekseevich Bogov
  • Publication number: 20170189489
    Abstract: A method of causing cardiomyocyte growth and/or differentiation, the method comprising exposing a cardiomyocyte to neuregulin (NRG) thereby activating the MAP kinase pathway in the cardiomyocyte and causing growth and/or differentiation of the cardiomyocyte. Use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins in the treatment or management of heart disease and heart failure in a mammal.
    Type: Application
    Filed: August 12, 2016
    Publication date: July 6, 2017
    Inventor: Mingdong Zhou
  • Publication number: 20170189490
    Abstract: The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.
    Type: Application
    Filed: March 15, 2017
    Publication date: July 6, 2017
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: HUNTINGTON POTTER, GARY W. ARENDASH, STEVEN BENNETT, TIMOTHY BOYD
  • Publication number: 20170189491
    Abstract: Provided is a composition containing neuropeptide Y for inhibiting side effects of anticancer agents. The neuropeptide Y of the present invention exhibits an effect of mitigating side effects, especially bone marrow injury and neurological disorders, occurring due to the administration of anticancer agents, and thus may be useful as an anticancer adjuvant which may mitigate side effects of anticancer agents and enhance the effect of anticancer agents.
    Type: Application
    Filed: July 14, 2015
    Publication date: July 6, 2017
    Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Jae Sung Bae, Hee Kyung Jin, Min Hee Park
  • Publication number: 20170189492
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: March 27, 2015
    Publication date: July 6, 2017
    Inventors: Anders Hasager Boss, Richard Petrucci
  • Publication number: 20170189493
    Abstract: The present invention provides compositions, devices, methods and processes related to the intradermal delivery of PTHrP and PTHrP analogues, particularly [Glu22,25, Leu23,28,31, Aib29, Lys26,30]hPTHrP(1-34)NH2.
    Type: Application
    Filed: November 14, 2016
    Publication date: July 6, 2017
    Inventors: Gary HATTERSLEY, Kris J. HANSEN, Amy S. DETERMAN, Ying ZHANG
  • Publication number: 20170189494
    Abstract: A histidine-free composition comprising: a high purity factor VIII (r-factor VIII); arginine and/or sucrose; a surface-active agent to prevent or at least inhibit surface adsorption of factor VIII; an amount of calcium chloride for specific stabilization of factor VIII.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 6, 2017
    Applicant: OCTAPHARMA AG
    Inventors: BRITA RIPPNER, JOSEFIN KNUTSSON, ULRIKA NILSSON, ELSA IVARSSON, ERÈNE AGERKVIST
  • Publication number: 20170189495
    Abstract: It is disclosed herein that microperoxidases are capable of binding carbon monoxide (CO) with high affinity and displacing CO from hemoglobin, thereby acting as CO scavengers. The present disclosure provides methods of treating carboxyhemoglobinemia (or CO poisoning) in a subject by administering a therapeutically amount of an isolated or recombinant microperoxidase. Methods of removing CO from hemoglobin in blood or tissue by administering a therapeutically amount of an isolated or recombinant microperoxidase are also described. Methods of determining the effectiveness of a microperoxidase for removing CO from hemoglobin are further described.
    Type: Application
    Filed: May 19, 2015
    Publication date: July 6, 2017
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Mark Thomas Gladwin, Jesus Tejero Bravo
  • Publication number: 20170189496
    Abstract: A method for the treatment and/or the prevention of a disease or a symptom related to dysfunction of regulatory T cell immunomodulation includes administering to a subject in need thereof compositions that regulate regulatory T cell immunomodulatory function, in which the compositions may be prepared by contacting starting materials with phosphorylation pathway-related factors, the agonists or the antagonists thereof. The phosphorylation pathway-related factors are selected from: proto-oncogene protein PIM1 and the coding sequence thereof. The regulation is achieved by regulating the activity of regulators of regulatory T cells selected from the group: FOXP3, IL-2, GITR, CTLA4, and a combination thereof.
    Type: Application
    Filed: March 9, 2017
    Publication date: July 6, 2017
    Applicant: Institut Pasteur of Shanghai, Chinese Academy of Sciences
    Inventors: Bin Li, Zhiyuan Li, Fang Lin, Zhimei Gao, Zuojia Chen, Andy Tsun, Kongchen Li
  • Publication number: 20170189497
    Abstract: A method for treating Pompe disease including administration of recombinant human acid ?-glucosidase having optimal glycosylation with mannose-6-phosphate residues in combination with an amount of miglustat effective to maximize tissue uptake of recombinant human acid ?-glucosidase while minimizing inhibition of the enzymatic activity of the recombinant human acid ?-glucosidase is provided.
    Type: Application
    Filed: December 29, 2016
    Publication date: July 6, 2017
    Inventors: Hung V. Do, Richie Khanna, Russell Gotschall
  • Publication number: 20170189498
    Abstract: The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell.
    Type: Application
    Filed: January 6, 2017
    Publication date: July 6, 2017
    Applicant: The MITRE Corporation
    Inventor: Michael Heath FARRIS
  • Publication number: 20170189499
    Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.
    Type: Application
    Filed: March 21, 2017
    Publication date: July 6, 2017
    Applicant: BIOM'UP
    Inventors: Christian GAGNIEU, Patricia FOREST, Sylvain PICOT
  • Publication number: 20170189500
    Abstract: This invention relates to novel uses of recombinant clostridial neurotoxins exhibiting decreased duration of effect, in particular uses for the treatment of patients having experienced muscle-related disorders and/or injuries.
    Type: Application
    Filed: June 12, 2015
    Publication date: July 6, 2017
    Inventors: Klaus FINK, Susanne GRAFE, Imke SCHULTZ, Susanna ROLL, Deryck JORDAN
  • Publication number: 20170189501
    Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
    Type: Application
    Filed: September 14, 2016
    Publication date: July 6, 2017
    Inventors: Joan M. Fallon, Matthew Heil, James Szigethy, James Fallon
  • Publication number: 20170189502
    Abstract: A first antigen is administered to a subject to select progenitor B cells that are suitable for subsequent production of a desirable affinity-matured antibody, and then a second antigen is administered to stimulate the expansion of B cells that produce that affinity-matured antibody. An immunization protocol is used in which two different antigens are administered (usually in series, but in some embodiment simultaneously), where the first antigen elicits an efficient germline antibody response and the second antigen elicits an efficient and desired affinity-matured antibody response.
    Type: Application
    Filed: December 14, 2016
    Publication date: July 6, 2017
    Inventor: Philip Dormitzer
  • Publication number: 20170189503
    Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
    Type: Application
    Filed: February 11, 2015
    Publication date: July 6, 2017
    Inventors: Alan Remaley, John T. Schillerr, Marcelo Amar, Bryce Chackerian